Date: 2014-08-29
Type of information: Fundraising
Company: Blueprint Genetics (Finland)
Investors: Inventure (Finland) Avohoidon Tutkimussäätiö (Finland)
Amount: $3.9 Million (€ 2.97 million)
Funding type: fundraising
Planned used: The funding allows the company to accelerate international expansion. Blueprint Genetics provides a clinical grade genetic diagnostics platform using a proprietary Next-Generation Sequencing (NGS) technology. The company uses a targeted sequencing technology that was developed in Stanford University, providing superior quality, lead-time, and cost-efficiency. The panel tests of the company are the most comprehensive on the market. In 2013, the company entered the market with its first product category, providing diagnostics for inherited cardiovascular disorders. Today, Blueprint Genetics serves more than 60 hospital customers in 10 countries, and is constantly expanding. The company is now launching its US office to boost sales in North America. Until today, a large part of clinical needs to diagnose inherited diseases has remained unaddressed due to the lack of sophisticated diagnostics. The proof of concept that Blueprint Genetics has received shows that with the right technology, NGS methods are ready for clinical use.
Others: * On August 29, 2014, Blueprint Genetics announced that Inventure and Avohoidon Tutkimussäätiö, a Finnish foundation, have joined the existing investors of the company. Previously, the company has been financed by Finnish business angels and Tekes, the Finnish Funding Agency for Innovation. The funding for Blueprint Genetics now totals $3.9 million, allowing the company to accelerate international expansion.
Therapeutic area: Technology - Services
